Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.2K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.2K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.2K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

2.0K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
2.0K
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.3K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.2K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Palliative care in systemic sclerosis: incorporating advance care planning into longitudinal care.

Journal of scleroderma and related disorders·2026
Same author

Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness.

ACR open rheumatology·2026
Same author

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Arthritis care & research·2026
Same author

Development and initial validation of a brief measure of uncertainty in rheumatic disease.

Journal of health psychology·2026
Same author

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

The Journal of rheumatology·2025

Related Experiment Video

Updated: Apr 15, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K

Interstitial lung disease in scleroderma.

Sara R Schoenfeld1, Flavia V Castelino1

  • 1Division of Rheumatology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

Rheumatic Diseases Clinics of North America
|April 4, 2015
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis, a complex autoimmune disease, often leads to interstitial lung disease, causing significant health issues. Current treatments are limited, but promising experimental therapies are under investigation.

Keywords:
DiagnosisFibrosisInterstitial lung diseasePathogenesisSystemic sclerosisTreatment

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

960
Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models
04:42

Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models

Published on: March 21, 2025

1.6K

Related Experiment Videos

Last Updated: Apr 15, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

960
Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models
04:42

Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models

Published on: March 21, 2025

1.6K

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Systemic sclerosis is a complex autoimmune disorder of unknown cause.
  • It involves autoimmunity, vasculopathy, and fibrosis, affecting multiple organs.
  • Interstitial lung disease (ILD) is a frequent and serious complication of systemic sclerosis.

Purpose of the Study:

  • To summarize the current understanding of systemic sclerosis and its impact on lung health.
  • To highlight diagnostic approaches for ILD in systemic sclerosis patients.
  • To review the limited therapeutic options and emerging experimental treatments for ILD in systemic sclerosis.

Main Methods:

  • Review of clinical evaluations.
  • Analysis of pulmonary function tests.
  • Interpretation of high-resolution computed tomography (HRCT) findings.

Main Results:

  • Systemic sclerosis presents heterogeneity with limited effective therapies.
  • ILD diagnosis requires integrated clinical, functional, and imaging data.
  • Few effective treatments exist, but early-phase trials show potential.

Conclusions:

  • Interstitial lung disease significantly impacts systemic sclerosis patient outcomes.
  • Accurate diagnosis of ILD is crucial for patient management.
  • Further research into novel therapies is essential for improving systemic sclerosis care.